Cellics Therapeutics

Cellics Therapeutics is committed to saving lives and improving patient health using innovative biomimetic nanomedicines. Its aim is to apply nanotechnology for the treatment and prevention of diseases. Its goal is to address severe diseases and highly unmet medical needs through innovative biomimetic nanomedicines. The company initially focuses primarily on autoimmune and inflammatory diseases, as well as difficult-to-treat infectious diseases. Additionally, Cellics is seeking to develop first-in-class vaccines for a variety of diseases. The company is currently on track to advance its lead candidate product, CTI-005, into human clinical trials for the treatment of bacterial pneumonia ahead of schedule. Utilizing advanced technology to promote human health and longevity is Cellics’ passion and mission.